The Bone-Myoregulation Reflex and Development of Sarcopenia in Osteoporosis

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Status: Completed

Conditions: Osteoporosis; Sarcopenia

Treatments: Device: whole-body vibration to Control

Study type: Interventional

Funder types: Other

Identifiers

NCT06017245

BMROPS

Details and patient eligibility

About

Bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally. The aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis

Full description

Bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally. While myokines synthesized and released in skeletal muscle modulate the bone formation and destruction process, osteokines synthesized and released by bone cells have positive or negative effects on muscle (4,5,6,7,8,9). In addition to humoral crosstalk mechanisms between muscle and bone, there is also a neuronal crosstalk mechanism defined as bone myoregulation reflex. The aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis (10,11,12,13,14). Osteoporotic cases would be determined by standard DXA measurements.

The vibration will be applied with the PowerPlate® Pro5 whole-body vibration (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.

Surface EMG recordings will be taken from the right soleus muscle using the bipolar technique. A pair of self-adhesive Ag/AgCl (Redline®) electrodes will be adhered to the skin according to the SENIAM protocol(2). Recordings will be taken in the 1-500 Hz frequency band. Surface electromyography (EMG) recordings will be taken with a PowerLab ® (ADInstruments, Oxford, UK) data recorder with a sample rate of 20 KHz. EMG recordings will be analyzed offline with LabChart7 Pro® version 7.3.8 (ADInstruments, Oxford, UK). The acceleration measurement data will be recorded with the PowerLab (ADInstrument London) data acquisition simultaneously with the EMG recording. Acceleration recording will be made with a sample rate of 20 KHz.

Enrollment: 60 patients

Sex: All

Ages: 20 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• For healthy young adults control Healthy volunteers aged 20-45 years
• For postmenopausal osteoporosis Hip DXA T-score (neck or total hip) < -2.5
• For the Senile osteoporosis Over 65 years Male Hip DXA T-score (neck or total hip) < -2.5 Female

Exclusion criteria

• Osteopenic cases
• Possible sarcopenia (according to EWGSOP2 criteria)
• Vertigo
• Kidney stone
• Panic attack story
• Secondary osteoporosis
• Those with polyneuropathy, central nervous system disease clinic/history
• Myopathies (steroid, vitamin D deficiency, primary muscle diseases, etc.)
• Cases with lesions on the soleus skin
• History of fracture in lower extremity, joint prosthesis
• Lower extremity active/acute thrombophlebitis

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 3 patient groups

Control

Active Comparator group

Description:

Healthy young-adult groups

Treatment:

Device: whole-body vibration to Control

Senile osteoporosis

Experimental group

Description:

Patients with senile osteoporosis

Treatment:

Device: whole-body vibration to Control

Postmenopausal osteoporosis

Experimental group

Description:

Patients with postmenopausal osteoporosis

Treatment:

Device: whole-body vibration to Control